GHO and CBC Forge $21 Billion Healthcare Investment Titan

LONDON and SINGAPORE – May 20, 2026 – In a move set to reshape the landscape of global healthcare finance, European specialist GHO Capital and Asian asset manager CBC Group have announced a definitive agreement to merge. The combination will create the world's largest investment firm exclusively dedicated to healthcare, commanding over USD 21 billion in assets under management (AUM) and establishing a powerhouse with unparalleled reach across the planet's most vital healthcare markets.

The new entity brings together two of the sector's most influential players, creating a single firm with more than 200 professionals operating out of 13 offices across North America, Europe, and the Asia-Pacific region. This vast network is strategically positioned to capitalize on innovation in regions that collectively account for approximately 90% of all global healthcare research and development spending.

A New Global Powerhouse in Healthcare Finance

The declaration to form the "world's largest dedicated healthcare investment manager" is more than just a press release headline; it's a significant recalibration of the private equity landscape. While diversified mega-firms like Carlyle Group manage healthcare-specific capital in the range of $20 billion, the new GHO-CBC entity stands out for its singular, unwavering focus on the sector. This specialization, combined with its sheer scale, positions it to compete directly with the healthcare divisions of giants like KKR and Blackstone, but with a more concentrated mission.

The merger is a combination of two nearly equal financial forces, with London-based GHO Capital managing US$10.5 billion in AUM and Singapore's CBC Group managing US$10.8 billion. The combined firm will be led by Co-Chief Executives Mike Mortimer, a co-founder of GHO, and Fu Wei, the founder and CEO of CBC Group, reflecting the partnership's balanced nature.

"We are reinforcing our position as dedicated healthcare specialists, expanding our global reach, deepening our value creation capabilities, and empowering our portfolio companies to compete and win in an increasingly dynamic global healthcare market," said Mike Mortimer, Managing Partner and Co-Founder of GHO Capital.

Bridging Continents for Innovation

The strategic core of the deal lies in its geographic synergy. GHO has built its reputation by backing and internationalizing healthcare companies across Europe and North America. CBC, meanwhile, has become Asia's largest healthcare-focused asset manager by employing a unique "investor-operator" model to build platforms in one of the world's fastest-growing markets.

The merger creates a two-way superhighway for innovation and capital. GHO's portfolio of Western companies gains a direct line to the operational expertise and market access needed to tap into the dynamic Asian healthcare frontier. Conversely, CBC's portfolio of promising Asian firms will receive the global market insights and execution support required to scale internationally with confidence. This integrated approach aims to shorten the distance between a breakthrough in a lab in Boston and its application in a hospital in Shanghai.

Fu Wei, Chief Executive Officer and Founder of CBC Group, framed the vision as one of global connectivity. "The combination is about connecting leading healthcare companies and innovations with the world's largest and most established markets and global pools of capital," he stated. "Together, we are building the world's largest dedicated healthcare investment firm to help accelerate patient access to affordable care, support innovation, and improve efficiency in addressing unmet medical needs."

The Strategic Bet on AI and Future Tech

Beyond geographic expansion, the new firm has placed a clear and strategic bet on the future of technology in medicine, particularly artificial intelligence. Lady Mireille Gillings, PhD, Co-Founder of GHO Capital and Co-Chair of the new board, emphasized this focus, noting, "AI is a fast-evolving force in healthcare and life sciences, and so AI applications in these fields will continue to be a focus moving forward."

This strategy aligns perfectly with broader investment trends. In 2025 alone, AI-focused healthcare companies accounted for nearly half of all healthcare investment dollars. Private equity is pouring capital into AI's potential to accelerate drug discovery, improve diagnostic accuracy, and streamline cumbersome hospital administration.

The firm's interest is not merely theoretical. GHO Capital’s existing portfolio already includes Scientist.com, an AI-powered platform that helps orchestrate R&D for pharmaceutical giants. This merger will provide the scale and capital to double down on such investments, seeking out transformative technologies in areas from medical devices and diagnostics to healthcare IT and infrastructure. By leveraging its global footprint, the firm can identify and scale AI-driven solutions that address healthcare challenges worldwide.

Navigating a Complex Path to Completion

Creating a global entity of this magnitude is a complex undertaking. The transaction is not expected to close until early 2027, a timeline that reflects the significant regulatory hurdles that must be cleared. The merger will require approval from antitrust and competition authorities in numerous key jurisdictions, including the European Union, the United States, the United Kingdom, China, and Singapore.

Until the deal is finalized, both GHO and CBC will continue to operate independently, managing their existing funds and portfolio companies as usual. The leadership structure for the new firm has been clearly defined, with GHO's Andrea Ponti and Alan MacKay overseeing group finance and governance, respectively. The board will be co-chaired by Lady Gillings and Fu Wei, ensuring a unified vision from the top.

The merger represents a pivotal moment, moving beyond simple consolidation to create a new blueprint for global healthcare investment. By combining regional expertise, deep operational involvement, and a forward-looking focus on technology, the unified firm is poised to not only generate strong returns but also play a significant role in shaping the delivery of healthcare on a global scale.